Skip to main
ACTU
ACTU logo

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics Inc has demonstrated significant improvement in overall survival (mOS) and one-year survival rates in patients with first-line metastatic pancreatic adenocarcinoma (mPDAC) when treated with elraglusib in combination with GnP, as presented at the 2025 ASCO annual meeting. The recent strengthening of the company's balance sheet through a fundraising initiative provides management with the financial flexibility to explore various regulatory pathways and potentially expedite the clinical development process for elraglusib. Additionally, the company's Phase 2 study results indicate a promising efficacy profile for elraglusib, suggesting that with further validation in larger trials, it could lead to favorable regulatory outcomes.

Bears say

Actuate Therapeutics has reported significant financial challenges, including rising operational costs that outpace revenue growth, leading to ongoing net losses. Additionally, the clinical stage of its therapeutic candidate, elraglusib, presents inherent risks associated with drug development, which may contribute to investor uncertainty and volatility in stock performance. Furthermore, the company's cash reserves raise concerns about its ability to fund continued research and development initiatives without securing additional financing, which could dilute existing shareholder value.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.